Androgen receptor is a determinant of melanoma targeted drug resistance

Melanoma provides a primary benchmark for targeted drug therapy. Most melanomas with BRAF(V600) mutations regress in response to BRAF/MEK inhibitors (BRAFi/MEKi). However, nearly all relapse within the first two years, and there is a connection between BRAFi/MEKi-resistance and poor response to immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Samarkina, Anastasia, Youssef, Markus Kirolos, Ostano, Paola, Ghosh, Soumitra, Ma, Min, Tassone, Beatrice, Proust, Tatiana, Chiorino, Giovanna, Levesque, Mitchell P., Goruppi, Sandro, Dotto, Gian Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576812/
https://www.ncbi.nlm.nih.gov/pubmed/37838724
http://dx.doi.org/10.1038/s41467-023-42239-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576812/
https://www.ncbi.nlm.nih.gov/pubmed/37838724
http://dx.doi.org/10.1038/s41467-023-42239-w

Ejemplares similares